Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q1 2021 · 10-Q
Revenue$622.00K$622.00Kno prior Q1 2020 on file Net Income-$5.32M-$5.32MN/M vs Q1 2020 EPS Diluted-$0.29-$0.29N/M vs Q1 2020 Operating Income-$5,372,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
Free Cash Flowderived-$5,646,000— Margins · derivedOperating margin-863.7%
Net margin-855.3%
ended Mar 31, 2021 · filed May 14, 2021 · 44 d after period end